Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls

Vaccine

Volumn 29, Issue 49, 2011, Pages 9276-9283

  Schmeink, Channa E ^a   Bekkers, Ruud L M ^a   Josefsson, Ann ^b   Richardus, Jan H ^c   Berndtsson Blom, Katarina ^d   David, Marie Pierre ^e   Dobbelaere, Kurt ^e   Descamps, Dominique ^e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Public Health Service of the Rotterdam Region   (Netherlands)

^d Ladulaas Kliniska Studier ^*  (Sweden)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adolescents; Hepatitis B vaccine; Human papillomavirus vaccine; Immunogenicity; Safety

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; WART VIRUS VACCINE;

ADJUVANT THERAPY; ADOLESCENT; ANKLE FRACTURE; APPENDICITIS; ARTICLE; CHILD; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FOREARM FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MULTICENTER STUDY; MYALGIA; NEPHROLITHIASIS; NORMAL HUMAN; OROPHARYNGEAL PAIN; OVARY CYST; PERIOSTITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SEROCONVERSION; SIDE EFFECT; STRESS; TREATMENT DURATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; CHILD; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNIZATION SCHEDULE; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SWEDEN;

EID: 82555164963     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.037     Document Type: Article

References (29)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
2. Bosch F.X., Lorincz A., Muñoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
3. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907.
4. Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., de S.S., Bruni L., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl. 10):K1-K16.
5. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
6. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
7. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
8. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
9. The GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
10. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De B.P., Zahaf T., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28:6247-6255.
11. Descamps D., Hardt K., Spiessens B., Izurieta P., Verstraeten T., Breuer T., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009, 5:332-340.
12. Rivera Medina D.M., Valencia A., de Velasquez A., Huang L.M., Prymula R., Garcia-Sicilia J., et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health 2010, 46:414-421.
13. World Health Organization Immunization, vaccines and biologicals. WHO vaccine-preventable diseases: monitoring system. 2010 global summary 2010, Available from: http://whqlibdoc.who.int/hq/2010/WHO_IVB_2010_eng.pdf [accessed 07.07.11].
14. Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.P., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008, 4:425-434.
15. Cambron P., Jacquet J.-M., Hoet B., Lievens M. Development and technical and clinical validation of a quantitative Enzyme-Linked Immunosorbent Assay for the detection of human antibodies to hepatitis B surface antigen in recipients of recombinant hepatitis B virus vaccine. Clin. Vaccine Immunol 2009, 16:1236-1246.
16. Mast E.E., Margolis H.S., Fiore A.E., Brink E.W., Goldstein S.T., Wang S.A., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54:1-31.
17. Gylca R., Gylca V., Benes O., Melnic A., Chicu V., Weisbecker C., et al. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth. Vaccine 2000, 19:825-833.
18. Wheeler C.M., Bautista O.M., Tomassini J.E., Nelson M., Sattler C.A., Barr E. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008, 26:686-696.
19. Garland S.M., Steben M., Hernandez-Avila M., Koutsky L.A., Wheeler C.M., Perez G., et al. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 2007, 14:792-795.
20. Garcia-Sicilia J., Schwarz T.F., Carmona A., Peters K., Malkin J.E., Tran P.M., et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health 2010, 46:142-151.
21. Leroux-Roels G., Abraham B., Fourneau M., De C.N., Safary A. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents. Vaccine 2000, 19:937-942.
22. Banatvala J.E., Van D.P. Hepatitis B vaccine - do we need boosters?. J Viral Hepat 2003, 10:1-6.
23. Schiff G.M., Sherwood J.R., Zeldis J.B., Krause D.S. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995, 16:12-17.
24. Wood R.C., MacDonald K.L., White K.E., Hedberg C.W., Hanson M., Osterholm M.T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. J Am Med Assoc 1993, 270:2935-2939.
25. Fisman D.N., Agrawal D., Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002, 35:1368-1375.
26. Wang C., Tang J., Song W., Lobashevsky E., Wilson C.M., Kaslow R.A. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004, 39:978-988.
27. Tong N.K., Beran J., Kee S.A., Miguel J.L., Sanchez C., Bayas J.M., et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005, 68:2298-2303.
28. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.
29. Pedersen C., Petaja T., Strauss G., Rumke H.C., Poder A., Richardus J.H., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007, 40:564-571.